Artificial Intelligence

Zoom launches a new grant program celebrating solo entrepreneurs using AI, signaling a strategic bet on the rapidly growing 'business of one' economy.

The investment giant's new podcast season tackles the energy trilemma, exploring AI's power thirst, the return of nuclear, and fossil fuel's role.

A new partnership arms independent cancer clinics with advanced AI and data analytics, aiming to improve patient care and ensure their survival.

A new class of painkillers promises the power of opioids with a far lower risk of addiction. Tris Pharma's cebranopadol could reshape pain management.

BEGA's new BEGA Connect platform leverages cloud power and NB-IoT to simplify architectural lighting control, eliminating servers and subscription fees.

ITRS's acquisition of French DEM leader IP-Label signals a major move to challenge market giants by creating a holistic observability platform for Europe.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

While humanoid robots grab headlines, Linkerbot quietly captured 80% of the dexterous hand market with revolutionary cost and production scale.

As the AI arms race heats up, Lambda brings in veteran operator Leonard Speiser to lead its $1.5B+ expansion and build the future of AI supercomputing.

The hospitality tech giant is leveraging its platform with a new AI assistant for retailers, aiming to automate inventory, boost margins, and challenge market leaders.

Vuzix wins a CES 2026 Innovation Award for its Ultralite Pro, smart glasses so discreet they look ordinary but pack powerful AI for the enterprise.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

With multiple clinical trials advancing and a savvy global expansion, RESTEM is poised to challenge the treatment paradigm for autoimmune disorders.

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.

At CES 2026, Hitachi unveiled major AI alliances with NVIDIA and Google, betting its HMAX platform can embed intelligence into the world's core systems.

The biotech firm launches an early access program for its novel platform, starting with a tau assay that could revolutionize Alzheimer's research.

A new partnership leverages in vivo screening to find novel obesity targets, aiming to revolutionize a market projected to exceed $100 billion.

The National Retail Federation partners with Insider One, using advanced AI to personalize its massive 2026 trade show for 40,000 attendees.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

Positive early human safety data for its lead drug and new candidates for Rett syndrome and MASH signal a pivotal year for ProQR's Axiomer technology.